Skip to main content

Table 1 Biologic treatments details: type of treatments (Eligible patients)

From: A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study

Reference biologic treatment line Eligible patients
N = 669
n (%)
Secukinumab (Cosentyx) 274 (41.0%)
Ustekinumab (Stelara) 169 (25.3%)
Adalimumab (Humira) 87 (13.0%)
Ixekizumab (Taltz) 81 (12.1%)
Certolizumab 19 (2.8%)
Etanercept (Enbrel) 17 (2.5%)
Etanercept (Benepali) 13 (1.9%)
Adalimumab (Amgevita) 5 (0.7%)
Golimumab 3 (0.4%)
Adalimumab (Imraldi) 1 (0.1%)